IOVA Hedge Fund Ownership (Q2 2026)

Iovance Biotherapeutics Inc (IOVA)

286 + Investors. Track Smart Money conviction in IOVA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — IOVA

Based on 290 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added IOVA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (97% of max)

97% of all-time peak

290 hedge funds hold IOVA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +17% more funds vs a year ago

fund count last 6Q

+43 new funds entered over the past year (+17% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟢

More buyers than sellers — 62% buying

180 buying111 selling

Last quarter: 180 funds were net buyers (48 opened a brand new position + 132 added to an existing one). Only 111 were sellers (67 trimmed + 44 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-21 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 39 → 53 → 69 → 48. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

54% of holders stayed for 2+ years

■ 54% conviction (2yr+) ■ 20% medium ■ 25% new

158 out of 290 hedge funds have held IOVA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +69% but shares only +7% — price-driven

Value

+68%

+7%

Last quarter: the total dollar value of institutional holdings rose +69%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

37 → 39 → 53 → 69 → 48 new funds/Q

New funds entering each quarter: 39 → 53 → 69 → 48. A growing number of institutions are discovering IOVA each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 61% veterans vs 26% newcomers

■ 61% veterans ■ 14% 1-2yr ■ 26% new

Entry-cohort mix of 301 holders: 183 (61%) are 2+ year veterans, 41 entered 1–2 years ago, and 77 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 67% AUM from top-100 funds

67% from top-100 AUM funds

51 of 289 holders are among the 100 largest funds by AUM, controlling 67% of total institutional value in IOVA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.8

out of 10

Low Exit Risk

Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	286	286	-
13F Shares	294M	276M	6.33%
Total Value	$1.20B	$945M	26.86%
New Positions	47	69	-22
Increased Positions	128	117	+11
Closed Positions	46	40	+6
Reduced Positions	62	59	+3
Total Calls	7	11	-36.36%
Total Puts	5	7	-28.57%
PUT/CALL Ratio	0.71	0.64	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

286

13F Shares

294M

276M

6.33%

Total Value

$1.20B

$945M

26.86%

New Positions

-22

Increased Positions

128

117

+11

Closed Positions

Reduced Positions

Total Calls

-36.36%

Total Puts

-28.57%

PUT/CALL Ratio

0.71

0.64

Neutral

Institutional Holders (2026 Q2)

286 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IOVA. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 IOVA holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Mhr Fund Management LLC	6.28%	28,967,103	$120.5M
2	Knott David M Jr	3.52%	1,600,000	$6.7M
3	Palo Alto Investors LP	3.04%	5,296,209	$22.0M
4	B Group, Inc.	2.93%	1,500,000	$6.2M
5	Orion Investment Co	2.52%	2,073,202	$8.6M
6	CM Management, LLC	1.19%	450,000	$1.9M
7	Xcelsior Advisor Partners LLC	0.98%	1,783,924	$7.4M
8	Kennondale Capital Management LLC	0.88%	318,188	$1.3M
9	Sector Gamma As	0.87%	968,466	$4.0M
10	Rhenman & Partners Asset Management AB	0.67%	1,705,327	$7.1M
11	Parametrica Management Ltd	0.64%	195,878	$815K
12	Mirador Capital Partners LP	0.55%	1,080,288	$4.5M
13	Invenomic Capital Management LP	0.37%	1,482,595	$6.2M
14	Sugar Maple Asset Management, LLC	0.36%	135,000	$562K
15	Rice Hall James & Associates, LLC	0.31%	1,539,840	$6.4M
16	Virtus Investment Advisers, LLC	0.28%	285,020	$1.2M
17	Long Focus Capital Management, LLC	0.22%	2,100,000	$8.7M
18	Scientech Research LLC	0.22%	65,757	$274K
19	Corsair Capital Management, L.P.	0.19%	370,000	$1.5M
20	QVT Financial LP	0.17%	678,564	$2.8M
21	Penbrook Management LLC	0.16%	61,945	$258K
22	Portland Investment Counsel INC.	0.15%	130,000	$541K
23	683 Capital Management, LLC	0.13%	644,300	$2.7M
24	Intellectus Partners, LLC	0.11%	151,846	$632K
25	Hennion & Walsh Asset Management, Inc.	0.10%	818,913	$3.4M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Iovance Biotherapeutics Inc (IOVA)

What does the Smart Money Trend signal show for IOVA?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added IOVA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IOVA?

More buyers than sellers — 62% buying: Last quarter: 180 funds were net buyers (48 opened a brand new position + 132 added to an existing one). Only 111 were sellers (67 trimmed + 44 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for IOVA holders?

Elite ownership — 67% AUM from top-100 funds: 51 of 289 holders are among the 100 largest funds by AUM, controlling 67% of total institutional value in IOVA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IOVA?

54% of holders stayed for 2+ years: 158 out of 290 hedge funds have held IOVA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Iovance Biotherapeutics Inc (IOVA)

Smart Money Signals — IOVA

Buying streak — 3 quarters in a row

At the ownership peak (97% of max)

Steady growth — +17% more funds vs a year ago

More buyers than sellers — 62% buying

Fewer new buyers each quarter (-21 vs last Q)

54% of holders stayed for 2+ years

Value +69% but shares only +7% — price-driven

Growing discovery — still being found

Veteran-anchored — 61% veterans vs 26% newcomers

Elite ownership — 67% AUM from top-100 funds

Institutional Sentiment Summary — IOVA

Hedge Fund Ownership: IOVA

Market Analysis: IOVA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: IOVA

Hedge Fund Positioning: IOVA

Statistics: IOVA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Iovance Biotherapeutics Inc (IOVA)

Welcome to 13Foresight!